SCHEMBL14920164

SCHEMBL14920164

CC(C)(C)OC(=O)NCc1ccc(F)c(Oc2ccc3c(c2)OCO3)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 4/20 0.40
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.40
RPS6KA1 Q15418 1/20 0.40
PKM P14618 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HSD17B10 Q99714 2/20 0.39
TP53 P04637 1/20 0.39
CRHBP P24387 1/20 0.39
RECQL P46063 1/20 0.39
CRHR2 Q13324 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14920678 0.81 RPS6KA1 (0.39) RPS6KA1
SCHEMBL14920199 0.78 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1RAB9ANPC1KDM4E
SCHEMBL30932891 0.74 SMN1; SMN2 (0.75) SMN1; SMN2ALDH1A1HPGDRAB9ANPC1
SCHEMBL14919976 0.74 MAPK1 (0.49) SMN1; SMN2ALDH1A1HPGDRAB9ANPC1
SCHEMBL22589144 0.73 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1HPGDRAB9ANPC1
SCHEMBL29467981 0.72 RPS6KA1 (0.42) RPS6KA1L3MBTL1
SCHEMBL19085509 0.72 RPS6KA1 (0.47) RPS6KA1L3MBTL1
SCHEMBL14920053 0.72 RPS6KA1 (0.42) RPS6KA1L3MBTL1
SCHEMBL19083121 0.71 RPS6KA1 (0.41) KDM4ERPS6KA1L3MBTL1LMNA
SCHEMBL506706 0.71 KDM4A (0.44) HPGDRAB9ANPC1PKMCRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2773613-A1 SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION Astex Therapeutics Limited (GB) 2014-09-10 EP disclosed
WO-2013064538-A1 SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION ASTEX THERAPEUTICS LIMITED (GB) 2013-05-10 WO disclosed